Children and young people encounter multiple forms of gender-based violence – an online course produced by an international project coordinated by Tampere University helps to identify and prevent it
24.1.2022 13:05:00 EET | Business Wire | Press release
Children and young people are exposed to a wide range of gendered violence. However, the phenomenon is poorly understood, which makes helping the victims difficult. The international Education and Raising Awareness in Schools to Prevent and Encounter Gender-Based Violence (EraseGBV) project, coordinated by Tampere University, produced an online course to help identify, prevent and address gender-based violence.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220124005334/en/
“Gender-based violence against children and youths is a little-known phenomenon. A better understanding of the issue by professionals working with children and young people is key to identifying violence and its consequences,” says Associate Professor Marita Husso from Tampere University. (Photo: Business Wire)
How do you approach young people who experience discrimination based on their gender expression? How do you deal with offensive images of your student, for example, on social media? And how do you address sexual violence faced by children or young people? Violence against children and youths is often referred to as bullying, even when it is considered assault by the Criminal Code.
“Gender-based violence against children and youths is a little-known phenomenon. A better understanding of the issue by professionals working with children and young people is key to identifying violence and its consequences,” says Associate Professor Marita Husso from Tampere University.
Husso leads the international Education and Raising Awareness in Schools to Prevent and Encounter Gender-Based Violence (EraseGBV) project coordinated by Tampere University, which has just published a free online course on encountering gender-based violence at schools in English, Finnish and Swedish. The training is also produced in Croatian, Spanish and Catalan.
It is a research-based e-learning package that develops new skills for those working in education, social work and health services. The training is aimed specifically at professionals working with 13–19-year-old teenagers but is also suitable for use with younger and older students. The training looks at the phenomenon from the perspectives of the person experiencing violence, the perpetrator, bystanders, and professionals and experts.
Schools play a pivotal role
Schools play a key role in identifying and addressing violence. The social environment of schools provides an opportunity to learn interaction skills and offers a unique opportunity to influence the perceptions and behaviour of children and young people. At the same time, it enables awareness-raising and change towards more equal relationships and more ethical practices.
“Addressing violence is a prerequisite for promoting equality and sustainable development. This new online training provides tools for preventing, identifying, and addressing violence. It provides information on such issues as digital violence, the impact of violence, good practices and legislation on the subject," says Husso.
“Getting help for problems of violence depends on the problem first being identified and addressed,” she emphasises.
The EraseGBV project has researched gender-based violence and ethical agency in schools and education in Finland, Croatia and Spain. The research partners comprise Tampere University; the University of Zagreb; Blanquerna Ramón Llull University; the Centre for Education, Counselling and Research (CESI); and Conexus.
For more information and instructions on how to register, please see the link to further information and the online course: https://projects.tuni.fi/erasegbv/training-programme/
Photo: In her future projects, Associate Professor Marita Husso will focus on promoting nonviolence and sustainable wellbeing and exploring harmful ideological, institutional and affective practices related to violence. Photo by Hanna-Kaisa Hämäläinen
Tampere University
The multidisciplinary Tampere University is the second largest university in Finland. The spearheads of our research and learning are technology, health, and society. The University is committed to addressing the greatest challenges that are facing our society and creating new opportunities. Almost all the internationally recognised fields of study are represented at the University. Together, Tampere University and Tampere University of Applied Sciences comprise the Tampere Universities community made up of more than 30,000 students and close to 5,000 employees. www.tuni.fi/en
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220124005334/en/
Contact information
Enquiries:
Associate Professor Marita Husso
Faculty of Social Sciences, Tampere University
marita.husso@tuni.fi, tel. +358503182510
University Researcher Satu Lidman
Faculty of Social Sciences, Tampere University
satu.lidman@tuni.fi
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
CorFlow Therapeutics Announces Successful Completion of Phase 1 and First Patients Enrolled in Phase 2 of the MOCA II Pivotal Trial, Approval to Start the REVITALISE RCT in Europe, and Strengthening of Clinical Leadership30.4.2026 14:00:00 EEST | Press release
CorFlow Therapeutics AG (CorFlow), a clinical-stage company focused on transforming the diagnosis and treatment for heart attack patients, today announced multiple milestones in advancing its clinical program and the strengthening of clinical leadership. Phase 1 of the company’s MOCA II FDA Pivotal Trial was successfully reached after safety and performance goals were met with STEMI heart attack patients who had the proprietary PCoFI diagnostic measurement of microvascular obstruction (MVO) made during a stenting procedure, when compared to the reference standard diagnosis by cardiac MRI in the subsequent days. Phase 1 included 19 patients enrolled across 5 US and 3 European sites. MOCA II follows the FIH MOCA I study and primarily aims to validate the threshold value of the proprietary PCoFI measurement for diagnosing MVO in the setting of primary angioplasty compared to cardiac MRI. This milestone achievement, which was confirmed by the study’s independent DSMB (Data and Safety Monit
Agendia to Present New Data Demonstrating the Expanded Clinical Utility of MammaPrint ® and BluePrint ® at the 2026 ESMO Breast Cancer Annual Congress30.4.2026 14:00:00 EEST | Press release
Agendia®, Inc., a leader in precision oncology for breast cancer, today announced it will present new data at the 2026 European Society for Medical Oncology (ESMO) Annual Congress on Breast Cancer, taking place May 6-8 in Berlin, Germany. The company will present two posters featuring data from the prospective FLEX Study and an independent post hoc analysis of the landmark MINDACT trial that underscore the prognostic value of MammaPrint® + BluePrint® in early-stage breast cancer (EBC). Poster #65P | Thursday, May 7, 13:15 – 14:15 p.m. CEST | Presenter: Elena Shagisultanova Prognostic Performance of MammaPrint in Patients with Small T1a, b, and c Node-Negative Early Breast Cancer A retrospective analysis from the FLEX Study involving 4,349 patients highlights the biological heterogeneity within small, node-negative (T1a, b, and c) tumors – a group that typically has favorable outcomes. MammaPrint (MP) identified a High Risk 2 (H2) subset, representing 10% of all patients and 5% of those
The Biggest Predictor of Business Growth Is Behavior30.4.2026 10:00:00 EEST | Press release
IDEO, the global design and innovation company, today announced the IDEO Innovation Quotient (IDEO IQ), a new report measuring how workplace behaviors drive business performance across 100 of the world’s largest companies. Those with the highest IDEO IQ scores earned nearly $20 billion in profit last year—50% higher than average and three times more than those ranked at the bottom. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260429978890/en/ The IDEO Innovation Quotient (IDEO IQ) is a new report measuring how workplace behaviors drive business performance across 100 of the world’s largest companies. The IDEO IQ surveyed 266 leaders in product and innovation roles at 100 of the world’s largest companies across the Media & Technology, Healthcare, and Consumer Goods sectors. The report is the first of its kind to draw a direct line between how companies operate internally and their financial performance. Companies were surve
Suzano Sells 12.7 Million Tonnes of Pulp for the First Time in Its History30.4.2026 01:22:00 EEST | Press release
Suzano(B3: SUZB3 | NYSE: SUZ), the world’s largest pulp producer, announces its results for the first quarter of 2026 (1Q26), achieving a new all‑time record in pulp sales. Over the 12‑month period from April 2025 to March 2026, the company sold 12.7 million tonnes of pulp, the highest volume ever recorded in its history. During the same period, Suzano also sold 1.7 million tonnes of paper across the packaging, printing and writing, specialty, and tissue segments. This unprecedented sales level mainly reflects the increase in production capacity following the start‑up of the Ribas do Rio Pardo pulp mill in the state of Mato Grosso do Sul, as well as Suzano’s strong operational efficiency across its production lines and supply chains, serving customers in more than 100 countries worldwide. In the first quarter of 2026, Suzano sold a total of 3.2 million tonnes, comprising 2.8 million tonnes of pulp and 378 thousand tonnes of paper. Net revenue amounted to BRL 11.0 billion, while adjuste
The Estée Lauder Companies Announces Minority Investment in Luxury Clinical Skin Care Brand 111SKIN29.4.2026 23:30:00 EEST | Press release
The Estée Lauder Companies Inc. (NYSE:EL) today announced a minority investment in 111SKIN, a luxury clinical skin care brand founded by renowned plastic and reconstructive surgeon Dr. Yannis Alexandrides. Terms of the investment were not disclosed. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260429495879/en/ 111SKIN's Reparative Collection Founded in 2012, 111SKIN was originally developed by Dr. Alexandrides to accelerate his patients’ healing time following procedures. At the heart of the brand is its innovative NAC Y2™, a pioneering complex designed to support skin repair and maintain a healthy, radiant and resilient complexion. Building on the foundation of this clinical expertise, 111SKIN has developed a portfolio of more than 30 products, anchored by its Black Diamond and Reparative collections and priced from $50 to $1,000. “Skin care is entering a new phase, shaped by the convergence of procedures, longevity and b
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
